Hyperliquid Strategies (PURR) Competitors

$6.99 -0.15 (-2.10%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$7.00 +0.01 (+0.19%)

As of 05/15/2026 07:59 PM Eastern

PURR vs. OGN, TWST, TNGX, ORKA, and BEAM

Should you buy Hyperliquid Strategies stock or one of its competitors? MarketBeat compares Hyperliquid Strategies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hyperliquid Strategies include Organon & Co. (OGN), Twist Bioscience (TWST), Tango Therapeutics (TNGX), Oruka Therapeutics (ORKA), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry.

How does Hyperliquid Strategies compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Hyperliquid Strategies (NASDAQ:PURR) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 9.4% of Hyperliquid Strategies shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Organon & Co. presently has a consensus price target of $11.40, indicating a potential downside of 14.89%. Hyperliquid Strategies has a consensus price target of $8.82, indicating a potential upside of 26.13%. Given Hyperliquid Strategies' stronger consensus rating and higher possible upside, analysts clearly believe Hyperliquid Strategies is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Organon & Co. had 1 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 5 mentions for Organon & Co. and 4 mentions for Hyperliquid Strategies. Organon & Co.'s average media sentiment score of 1.23 beat Hyperliquid Strategies' score of 0.70 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperliquid Strategies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than Hyperliquid Strategies. Hyperliquid Strategies is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.40
Hyperliquid Strategies	$1M	941.01	-$16.01M	-$7.37	N/A

Organon & Co. has a net margin of 3.99% compared to Hyperliquid Strategies' net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Summary

Organon & Co. beats Hyperliquid Strategies on 11 of the 16 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Hyperliquid Strategies (NASDAQ:PURR) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Twist Bioscience has a beta of 2.22, meaning that its stock price is 122% more volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

Hyperliquid Strategies has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Twist Bioscience's return on equity of -26.73% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Hyperliquid Strategies has lower revenue, but higher earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	8.13	-$77.67M	-$1.33	N/A
Hyperliquid Strategies	$1M	941.01	-$16.01M	-$7.37	N/A

9.4% of Hyperliquid Strategies shares are held by institutional investors. 3.1% of Twist Bioscience shares are held by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Twist Bioscience had 4 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 8 mentions for Twist Bioscience and 4 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.70 beat Twist Bioscience's score of 0.69 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperliquid Strategies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Twist Bioscience presently has a consensus price target of $56.57, indicating a potential upside of 15.05%. Hyperliquid Strategies has a consensus price target of $8.82, indicating a potential upside of 26.13%. Given Hyperliquid Strategies' higher possible upside, analysts clearly believe Hyperliquid Strategies is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Twist Bioscience and Hyperliquid Strategies tied by winning 8 of the 16 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Tango Therapeutics?

Hyperliquid Strategies (NASDAQ:PURR) and Tango Therapeutics (NASDAQ:TNGX) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Hyperliquid Strategies has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Hyperliquid Strategies has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -41.54% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Tango Therapeutics	-151.15%	-41.54%	-33.44%

Hyperliquid Strategies has higher earnings, but lower revenue than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	941.01	-$16.01M	-$7.37	N/A
Tango Therapeutics	$56.99M	52.04	-$101.59M	-$0.83	N/A

9.4% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Tango Therapeutics had 9 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 13 mentions for Tango Therapeutics and 4 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.70 beat Tango Therapeutics' score of 0.68 indicating that Hyperliquid Strategies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hyperliquid Strategies presently has a consensus price target of $8.82, indicating a potential upside of 26.13%. Tango Therapeutics has a consensus price target of $32.27, indicating a potential upside of 56.97%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Tango Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Tango Therapeutics beats Hyperliquid Strategies on 9 of the 16 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Oruka Therapeutics?

Hyperliquid Strategies (NASDAQ:PURR) and Oruka Therapeutics (NASDAQ:ORKA) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Hyperliquid Strategies has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	941.01	-$16.01M	-$7.37	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.86	N/A

Oruka Therapeutics' return on equity of -26.16% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Oruka Therapeutics	N/A	-26.16%	-25.00%

Hyperliquid Strategies has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.2, indicating that its share price is 120% less volatile than the broader market.

In the previous week, Oruka Therapeutics had 11 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 15 mentions for Oruka Therapeutics and 4 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.70 beat Oruka Therapeutics' score of 0.54 indicating that Hyperliquid Strategies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hyperliquid Strategies presently has a consensus price target of $8.82, indicating a potential upside of 26.13%. Oruka Therapeutics has a consensus price target of $120.80, indicating a potential upside of 95.06%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

9.4% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Oruka Therapeutics beats Hyperliquid Strategies on 9 of the 14 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Hyperliquid Strategies (NASDAQ:PURR) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Hyperliquid Strategies has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	20.56	-$79.99M	-$0.68	N/A
Hyperliquid Strategies	$1M	941.01	-$16.01M	-$7.37	N/A

Hyperliquid Strategies has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Beam Therapeutics has a beta of 2.26, meaning that its stock price is 126% more volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

In the previous week, Beam Therapeutics had 18 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 22 mentions for Beam Therapeutics and 4 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.70 beat Beam Therapeutics' score of -0.10 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hyperliquid Strategies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics presently has a consensus price target of $46.83, indicating a potential upside of 67.68%. Hyperliquid Strategies has a consensus price target of $8.82, indicating a potential upside of 26.13%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Beam Therapeutics is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 9.4% of Hyperliquid Strategies shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Beam Therapeutics beats Hyperliquid Strategies on 11 of the 17 factors compared between the two stocks.

Get Hyperliquid Strategies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PURR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PURR vs. The Competition

Export

Metric	Hyperliquid Strategies	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$961.20M	$2.94B	$4.74B	$12.48B
Dividend Yield	N/A	15.19%	5.93%	5.25%
P/E Ratio	-0.95	12.99	22.92	25.24
Price / Sales	941.01	1,854.96	115.01	82.25
Price / Cash	N/A	26.88	50.14	56.04
Price / Book	1.27	5.97	38.26	6.90
Net Income	-$16.01M	-$42.19M	$113.55M	$334.66M
7 Day Performance	4.17%	-0.70%	2.46%	0.13%
1 Month Performance	8.37%	1.47%	4.53%	1.11%
1 Year Performance	N/A	16.27%	16.78%	30.62%

Hyperliquid Strategies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PURR Hyperliquid Strategies	2.9797 of 5 stars	$6.99 -2.1%	$8.82 +26.1%	N/A	$961.20M	$1M	N/A	N/A	Gap Down
OGN Organon & Co.	2.8406 of 5 stars	$13.32 -0.1%	$11.40 -14.4%	+52.0%	$3.50B	$6.22B	14.32	10,000	Positive News
TWST Twist Bioscience	2.4954 of 5 stars	$55.95 -0.5%	$56.57 +1.1%	+63.4%	$3.50B	$376.57M	N/A	990	Insider Trade Gap Down
TNGX Tango Therapeutics	2.8799 of 5 stars	$23.50 +0.1%	$22.44 -4.5%	+1,252.6%	$3.39B	$62.38M	N/A	90	News Coverage Earnings Report Analyst Forecast Gap Down
ORKA Oruka Therapeutics	3.3631 of 5 stars	$64.65 -1.6%	$120.80 +86.9%	+554.7%	$3.30B	N/A	N/A	N/A	Earnings Report Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PURR) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperliquid Strategies (PURR) Competitors

PURR vs. OGN, TWST, TNGX, ORKA, and BEAM

How does Hyperliquid Strategies compare to Organon & Co.?

Summary

How does Hyperliquid Strategies compare to Twist Bioscience?

Summary

How does Hyperliquid Strategies compare to Tango Therapeutics?

Summary

How does Hyperliquid Strategies compare to Oruka Therapeutics?

Summary

How does Hyperliquid Strategies compare to Beam Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PURR vs. The Competition

Hyperliquid Strategies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hyperliquid Strategies (PURR) Competitors

PURR vs. OGN, TWST, TNGX, ORKA, and BEAM

How does Hyperliquid Strategies compare to Organon & Co.?

Do institutionals & insiders believe in OGN or PURR?

Do analysts rate OGN or PURR?

Does the media refer more to OGN or PURR?

Which has more risk & volatility, OGN or PURR?

Which has higher valuation & earnings, OGN or PURR?

Is OGN or PURR more profitable?

Summary

How does Hyperliquid Strategies compare to Twist Bioscience?

Which has more risk & volatility, TWST or PURR?

Is TWST or PURR more profitable?

Which has higher valuation & earnings, TWST or PURR?

Do institutionals & insiders believe in TWST or PURR?

Does the media refer more to TWST or PURR?

Do analysts rate TWST or PURR?

Summary

How does Hyperliquid Strategies compare to Tango Therapeutics?

Which has more volatility & risk, PURR or TNGX?

Is PURR or TNGX more profitable?

Which has preferable valuation & earnings, PURR or TNGX?

Do institutionals & insiders believe in PURR or TNGX?

Does the media refer more to PURR or TNGX?

Do analysts recommend PURR or TNGX?

Summary

How does Hyperliquid Strategies compare to Oruka Therapeutics?

Which has preferable valuation & earnings, PURR or ORKA?

Is PURR or ORKA more profitable?

Which has more volatility & risk, PURR or ORKA?

Does the media refer more to PURR or ORKA?

Do analysts recommend PURR or ORKA?

Do institutionals & insiders believe in PURR or ORKA?

Summary

How does Hyperliquid Strategies compare to Beam Therapeutics?

Which has higher earnings and valuation, BEAM or PURR?

Is BEAM or PURR more profitable?

Which has more volatility & risk, BEAM or PURR?

Does the media prefer BEAM or PURR?

Do analysts rate BEAM or PURR?

Do insiders and institutionals have more ownership in BEAM or PURR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PURR vs. The Competition

Hyperliquid Strategies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools